UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)

Recruiting

• Conditions: Non Alcoholic Fatty Liver Disease

• Registration Number: NCT06080386
• Lead Sponsor: University Hospital, Angers

Brief Summary

The purpose of this study is to assess UDFF performance (compared to MRI)

Detailed Description

Not available

Study Timeline

• Study Start: 2022-03-01
• Primary Completion: 2023-09-01
• Status Verified: 2023-10
• Study First Submitted: 2023-10-06
• Study First Submitted QC: 2023-10-06
• Last Update Submitted: 2023-10-06
• Study First Posted: 2023-10-12
• Last Update Posted: 2023-10-12
• Study Completion: 2023-10-15

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• All patients who had hepatic ultrasound with available UDFF measurements and hepatic MRI (with steatosis quantification sequences) between 01/01/2022 and 31/09/2023 may be included.

Exclusion Criteria

• chronic liver disease with a different etiology other than NAFL/NASH or mixed (hepatitis B or C, hemochromatosis, autoimmune hepatitis, Wilson's disease, cholestasic disease, alpha 1 antitrypsin deficiency),
• decompensated cirrhosis (ascites, jaundice, encephalopathy, rupture of esophageal varices),
• hepatocellular carcinoma.
• opposition to the use of its data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the perfomances of the UDFF system for the quantification of hepatic steatosis in patients suspected of chronic hepatophyte.	3 months maximum between the 2 measurements (UDFF and MRi)	Steatosis value measured by multiecho sequences in MR

Trial Locations

Locations (1)

Angers university hospital; 🇫🇷 Angers, France